Related by context. All words. (Click for frequent words.) 69 Scale EDSS 69 CCyR 69 EDSS scores 69 oxycodone CR 69 Expanded Disability Status 69 receiving golimumab 68 HBeAg seroconversion 68 PASI scores 68 cytogenetic response 68 binary restenosis 68 DAS# remission 68 severe exacerbations 68 complete cytogenetic response 68 ACR# response 68 baseline HbA1c 68 lumbar spine BMD 68 achieved ACR# 68 morphometric vertebral fractures 67 corticosteroid dose 67 tipranavir r 67 log# IU mL 67 moderate renal impairment 67 EDSS score 67 venlafaxine XR 67 Montgomery Asberg Depression 67 Crohn Disease Activity 67 Free Survival PFS 66 MADRS score 66 chlorambucil 66 serum phosphate 66 tapentadol ER 66 definite stent thrombosis 66 placebo p = 66 QTcF 66 % Confidence Interval 66 Scale EDSS score 66 Index CDAI 66 #.#/#.# mmHg [001] 66 virologic response 66 biochemical relapse 66 CDAI score 66 gout flares 66 FOLFOX4 66 deep venous thromboses 66 APTIVUS r 66 complete cytogenetic 66 achieved CCyR 66 Hb A1C 66 pCR 66 virologic failure 66 certolizumab 65 estimated glomerular filtration 65 sustained virologic response 65 fosamprenavir 65 8mg/kg 65 sUA 65 plasma HCV RNA 65 mL/min/#.# m 2 65 pulmonary exacerbations 65 receiving prophylactic anticoagulation 65 clodronate 65 lopinavir r arm 65 VELCADE melphalan 65 placebo dexamethasone 65 atazanavir ritonavir 65 TEAEs 65 Natalizumab 65 glycated hemoglobin levels 65 nonvertebral fractures 65 sustained virological response 65 Relapsing Remitting Multiple Sclerosis 65 CrCl 65 serum urate 64 CR nPR 64 mg kg dose 64 PSADT 64 Sustained virologic response 64 progression TTP 64 % CI #.#-#.# [003] 64 ULORIC 64 prednisone prednisolone 64 recurrent VTE 64 TAXUS p value 64 HbA1c levels 64 confirmed CCyR 64 secondary efficacy endpoint 64 plus prednisone 64 A1c levels 64 CIMZIA TM certolizumab pegol 64 mucosal healing 64 postoperative mortality 64 elevated ALT 64 PREZISTA r arm 64 MCyR 64 Response Evaluation Criteria 64 plus dexamethasone 64 arterial thromboembolic events 64 ACTEMRA TM 64 Rating Scale MADRS 64 plus MTX 64 hip BMD 64 ACR# responses 64 -#.# log# 64 FluCAM 64 HDRS 64 PegIFN RBV 64 receiving INTRON 64 alanine aminotransferase ALT 64 rimonabant #mg 64 plus OBT 64 RLAI 64 reinfarction 64 oral FTY# 63 #mg BID [001] 63 XIENCE V PROMUS Stent 63 HBeAg positive patients 63 CR CRu 63 plus methotrexate 63 HAM D# scores 63 mg BID 63 adjunctive placebo 63 Psoriasis Area 63 NMIBC 63 TNF antagonist 63 mcg QD 63 CIMZIA TM 63 detectable HCV RNA 63 HbA 1c levels 63 #.#mg/dL 63 abacavir lamivudine 63 Kaplan Meier estimates 63 HBeAg negative patients 63 cEVR 63 CDAI 63 PSA nadir 63 discontinuations due 63 placebo fluoxetine 63 Secondary endpoints include 63 periprocedural 63 PREZISTA r 63 postintervention 63 Doxil ® 63 rapid virologic response 63 albumin excretion rate 63 REYATAZ r arm 63 angiographic restenosis 63 placebo p 63 nondiabetic patients 63 recurrent glioblastoma multiforme 63 serum potassium 63 Lupuzor ™ 63 mitoxantrone plus 63 MS relapses 63 plus prednisone prednisolone 63 Solid Tumors criteria 63 IOP lowering 63 irbesartan 63 aminotransferase elevations greater 63 adalimumab Humira 63 steroid dexamethasone 63 relapsed MM 63 bortezomib refractory 63 T2 lesion volume 63 response CCyR 63 CIMZIA ™ 63 STRIDE PD 63 HAQ DI 63 receiving APTIVUS r 63 #mg BID [003] 63 flutamide 63 adefovir treated 63 tolterodine ER 63 -#.# log# copies mL 63 -#.# mg dL [002] 63 hemoglobin A1c HbA1c 63 mg ustekinumab 63 Secondary endpoints 63 adjunctive ABILIFY 63 acute gout flares 63 NATRECOR R 63 mg QD 63 nicardipine 63 liver histology 63 lispro 63 achieved statistical significance 63 hyperphenylalaninemia HPA due 62 log# copies mL 62 serum testosterone 62 creatinine clearance 62 mcg BID 62 ritonavir boosted 62 statistically significant p = 62 desvenlafaxine succinate 62 elevated transaminases 62 ziprasidone 62 mg BID dose 62 serum calcium levels 62 platelet reactivity 62 insulin detemir 62 mcg kg REBETOL 62 quetiapine XR 62 Kaplan Meier analysis 62 HbA1C levels 62 sUA levels 62 seropositive patients 62 Folfox 62 serum clusterin levels 62 severe neutropenia 62 β blocker 62 nonvertebral fracture 62 glycated hemoglobin HbA1c 62 UACR 62 radiographic progression 62 confidence interval #.#-#.# 62 fasting plasma glucose FPG 62 XIENCE V vs. 62 baseline LDH 62 dalteparin 62 PEGylated interferon beta 1a 62 relapsed CLL 62 virological response 62 FOLFIRI 62 aspartate aminotransferase 62 clinically meaningful improvement 62 intravascular hemolysis 62 infliximab monotherapy 62 mmHg diastolic 62 endoscopic remission 62 YMRS 62 neurologic progression 62 eplerenone 62 TMC# r 62 alanine aminotransferase 62 thromboembolic events 62 perioperative complications 62 adenoma recurrence 62 hypoglycemic events 62 nonfatal MI 62 #q# deletion syndrome 62 MACCE 62 mcg Albuferon 62 log# reduction 62 p = NS 62 calculated creatinine clearance 62 serum urate levels 62 antiretroviral naive 62 CI #.#-#.# [001] 62 lumbar spine bone 62 COPAXONE R 62 peginterferon alfa 2a 62 Flu Cy 62 p = .# [002] 62 #mg dose [003] 62 CDI recurrence 62 dapagliflozin plus 62 free survival PFS 62 Oral Fingolimod 62 asymptomatic carotid stenosis 62 Ishak fibrosis score 62 AVONEX ® 62 cardiovascular hospitalizations 62 % CI #.#-#.# [006] 62 glomerular filtration 62 glycosylated hemoglobin HbA1c 62 severe renal impairment 62 Platelet counts 62 Sustained Virological Response 62 undetectable viral load 62 microbiological eradication 62 virological failure 62 #.#/#.# mm Hg [003] 62 abnormal p# biomarker 61 baseline A1C 61 ALT elevation 61 interferon ribavirin 61 Hazard Ratio 61 serum phosphorous 61 ertapenem 61 postoperative inflammation 61 % CI #.#-#.# [007] 61 Primary endpoints 61 polyp recurrence 61 seroprotection 61 tirofiban 61 aspartate aminotransferase AST 61 systemic embolism 61 titrated glipizide 61 cilostazol 61 statistical significance p 61 Index CDAI score 61 p = #.# [003] 61 5-FU/LV 61 COPD exacerbation 61 PRADAXA #mg 61 prednisone prednisolone plus 61 median CD4 61 splenectomized patients 61 mcg albinterferon alfa 2b 61 confidence interval CI 61 #mg/day [002] 61 foveal thickness 61 RECIST Response Evaluation Criteria 61 HBeAg 61 serum creatinine levels 61 ipsilateral stroke 61 tapentadol IR 61 ribavirin therapy 61 serum prostate 61 unfractionated heparin UFH 61 IFN α 61 liver enzymes ALT 61 DAS# CRP 61 imatinib therapy 61 DAS# [002] 61 Thal Dex 61 octreotide LAR 61 serologically active patients 61 prospectively stratified 61 Operative mortality 61 ischemia driven 61 HOMA IR 61 NPH insulin 61 overt hepatic encephalopathy HE 61 FDA defined valvulopathy 61 alemtuzumab treated 61 T2DM 61 mcg mL 61 estramustine 61 neutrophil counts 61 preintervention 61 TDF FTC 61 tipranavir 61 FOLPI 61 serum estradiol 61 mmol l 61 advanced adenoma 61 dose Iluvien 61 methotrexate monotherapy 61 recurrent venous thromboembolism 61 Non inferiority 61 serum HBV DNA 61 Stent thrombosis 61 BENICAR HCT 61 incontinence episodes 61 salmeterol fluticasone 61 achieved sustained virological 61 FASLODEX 61 FIRMAGON 61 mild renal insufficiency 61 repeat paracentesis 61 salmeterol HFA MDI 61 imipenem 61 atypical ductal hyperplasia 61 anthracycline taxane 61 HER2 overexpression 61 lymphocytosis 61 Alzheimer Disease Assessment 61 mg kg Hematide 61 refractory NSCLC 61 mg qd 61 mg TID 61 genotypic resistance 61 nausea photophobia 61 atherothrombotic events 61 metastatic GIST 61 REMICADE monotherapy 61 ug kg 61 Secondary endpoints included 61 candesartan cilexetil 61 RECIST criteria 61 CVD mortality 61 4mg/kg 61 ARCOXIA 61 mRS 61 CK # plasma concentrations 61 RSV hospitalizations 61 tumor shrinkage 61 μmol L 61 -#.# mg dL [001] 61 carotid IMT 60 recurrent ischemia 60 5 Fluorouracil 60 IIIa inhibitor 60 extrapyramidal symptoms 60 iPTH 60 CYPHER Stent 60 systemic corticosteroid 60 undetectable HCV RNA 60 Target Lesion Revascularization TLR 60 mcg kg 60 Subgroup analysis 60 colorectal adenoma 60 ATACAND 60 tipranavir ritonavir 60 TLUS 60 evaluable subjects 60 adalimumab 60 Fasting blood glucose 60 receiving PEGINTRON 60 fluticasone salmeterol 60 ADCS CGIC 60 Relapsing Multiple Sclerosis 60 postoperative AF 60 STELARA ® 60 serum phosphate levels 60 Treatment Naive Patients 60 % CI #.#-#.# [008] 60 BARACLUDE ® 60 ACR Pedi 60 ZOLINZA 60 ARCALYST ® 60 solifenacin 60 Severity MSCS score 60 prolactin levels 60 urinary cortisol 60 R# #mg BID 60 blood phenylalanine Phe 60 Viral load 60 postprocedure 60 Patients Receiving 60 adriamycin 60 atorvastatin #mg 60 NIHSS score 60 #mg q8h 60 DOXIL 60 SVR# 60 serum concentrations 60 Score DAS# 60 serum aminotransferase levels 60 paraprotein 60 quetiapine 60 Events MACE 60 HBV DNA 60 HES CEL 60 HBV DNA levels 60 median PFS 60 galiximab 60 carboplatin paclitaxel 60 BENICAR 60 rosuvastatin #mg 60 #mg/m# [001] 60 vincristine doxorubicin 60 #mg/day [001] 60 weekly CSBMs 60 retinal thickness 60 pyrexia mucositis sepsis febrile 60 FOLFOX4 alone 60 dacarbazine DTIC 60 β blockers 60 dexamethasone Decadron 60 ibandronate 60 inhospital 60 blastic phase 60 HbA1C 60 primary hypercholesterolemia 60 nonfatal myocardial infarction 60 clomipramine 60 IFN beta 60 extrapyramidal side 60 nadroparin 60 CRp 60 alfa 2a 60 prolactin elevation 60 IU ml 60 salmeterol inhalation powder 60 cis retinoic acid 60 DAPT 60 heavily pretreated 60 lamivudine monotherapy 60 XIENCE V demonstrated 60 atheroma volume 60 urate lowering therapy 60 highly emetogenic 60 Timed Walk 60 intima media thickness 60 SSRI SNRI 60 HbA 1c 60 CI #.#-#.# [002] 60 symptomatic intracranial hemorrhage 60 mg p = 60 glomerular filtration rate 60 antiandrogen 60 Pharmacokinetic parameters 60 LEXIVA 60 aldosterone antagonist 60 anemia hemoglobin 60 neutropenia dehydration dyspnea 60 chemoradiation therapy 60 myelodysplastic myeloproliferative diseases 60 NIHSS 60 evaluating tivozanib 60 LVEF 60 #mg dose [002] 60 clinically meaningful improvements 60 #mg QD [002] 60 SELENA SLEDAI score 60 plasma cortisol 60 oral allopurinol 60 undetectable viral 60 prospectively defined 60 androgen suppression 60 severe hypoglycemic 60 gastric pH 60 biochemical recurrence 60 splenectomized 60 Castration Resistant Prostate Cancer 60 Median progression 60 specific antigen PSA 60 mycophenolate mofetil 60 antiarrhythmic drug 60 adefovir 60 x ULN 59 EXJADE 59 mg simvastatin 59 Montgomery Åsberg Depression 59 mesalamine granules 59 serum ALT 59 azacitidine 59 protein excretion 59 lopinavir r 59 trimethoprim sulfamethoxazole 59 mmHg p = 59 ALND 59 Brief Psychiatric 59 limiting toxicity 59 interferon beta therapy 59 FOLFOX6 59 trastuzumab Herceptin ® 59 log# 59 pioglitazone 59 evaluable patients 59 q#h 59 serum phosphorus 59 HER2 expression 59 recurrent atrial fibrillation 59 venlafaxine Effexor 59 COPD exacerbations 59 paricalcitol 59 Meets Primary Endpoint 59 urinary N telopeptide 59 divalproex sodium 59 copies mL 59 symptom exacerbation 59 q8h 59 serum HCV RNA 59 ximelagatran 59 KRAS mutant tumors 59 lanthanum carbonate 59 mean baseline A1C 59 metastatic malignant 59 CNS LS 59 FluCAM arm 59 clinically meaningful reductions 59 pT3 59 statistically significant p 59 tumor recurrence 59 IRLS score 59 remission CR 59 rFSH 59 leukemia AML 59 moderate hepatic impairment 59 relapsing MS 59 docetaxel chemotherapy 59 CLARITY study 59 aminotransferase levels 59 bronchopulmonary dysplasia 59 XELOX 59 CsA 59 Capacity FVC 59 serum uric acid 59 oral antidiabetes 59 refractory ischemia 59 SGPT 59 oblimersen 59 nonadherence 59 ACE inhibitor ramipril 59 ALT flares 59 #mmHg [001] 59 Hepatotoxicity 59 oral diclofenac 59 oral antidiabetic medication 59 CK # plasma 59 vertebral fracture 59 daunorubicin 59 fondaparinux 59 Pred Forte 59 PROCTOCORT ® Suppository Hydrocortisone 59 postoperative chemotherapy 59 tiotropium 59 decitabine 59 QTc 59 CYP#A# substrate 59 CI -#.# 59 bronchial hyperresponsiveness 59 Solid Tumors 59 low dose Iluvien 59 zonisamide SR 59 INCB# [003] 59 nadolol 59 experienced virologic failure 59 IPSS 59 thromboembolism 59 inflammatory lesions 59 hematologic toxicity 59 recurrent genital herpes 59 Scale cognitive subscale 59 recurrent DVT 59 Thrombocytopenia 59 cabazitaxel 59 aminotransferases 59 A1C levels 59 target lesion revascularization 59 hemoglobin A1c levels 59 Score TOS 59 DMARD 59 plasma uric acid 59 fibrinolysis 59 perioperative mortality 59 risedronate 59 proteinuria 59 APTIVUS ritonavir 59 nucleoside naive 59 peripheral sensory neuropathy 59 detrusor overactivity 59 tenofovir emtricitabine 59 generalized edema 59 nonfasting triglyceride levels 59 mean baseline HbA1c 59 baseline PASI 59 teriflunomide 59 stage IIIb IV 59 pulmonary exacerbation 59 linaclotide treated 59 dacarbazine 59 Acetate Rectal Suppositories 59 oral vancomycin 59 anthracyclines taxanes 59 confidence intervals CIs 59 hypoglycaemic episodes 59 creatinine ratio 59 3mg/kg 59 KRAS mutations occur 59 symptomatic VTE 59 mitoxantrone 59 pegylated liposomal doxorubicin 59 invasive aspergillosis 59 intravitreal injections 59 ng dL 59 mm Stent 59 rizatriptan 59 locoregional recurrence 59 alteplase 59 FOLPI regimen 59 dosing frequency 59 Health Assessment Questionnaire 59 macroalbuminuria 59 bioavailable testosterone 59 standard chemotherapy regimen 59 GnRH agonist 59 mEq L 59 oxycodone IR 59 draining enterocutaneous 59 fasting plasma glucose 59 SCIg 59 PLX STROKE targeting 59 Newly Diagnosed Patients 59 gemcitabine carboplatin 59 systolic BP 59 virologic breakthrough 59 Hypotension 59 nilotinib 59 WOMAC TM 59 bone marrow reticulin 59 CIN3 59 naïve HCV 59 urinary albumin excretion 59 elotuzumab 59 ARB telmisartan 59 mRCC 59 microvessel density 59 PEG IFN 59 Pegylated Liposomal Doxorubicin 59 PREZISTA ritonavir 59 candesartan 59 Lucentis monotherapy 59 upper gastrointestinal bleeding 59 ACR# ACR# 59 Infusion Reactions Severe 58 Pharmacokinetics PK 58 sotalol 58 mg/m2/day 58 leukocyte count 58 benazepril 58 neurodevelopmental impairment 58 #mg dose [001] 58 posttreatment 58 FUSILEV enhances 58 baseline FEV 58 CANCIDAS 58 amoxicillin clavulanate 58 serum transaminases 58 bosentan 58 low dose cytarabine 58 TPV r 58 intravenous bisphosphonates 58 abdominal pain abdominal discomfort 58 6MWD 58 viral kinetics 58 Monotherapy 58 del 5q MDS 58 Unstable Angina 58 telaprevir dosed 58 LEXIVA r 58 HBeAg + 58 RAPTIVA 58 APTIVUS R 58 Peginterferon 58 ug dose 58 leucopenia 58 Demonstrate Significant 58 exemestane 58 antibody titer 58 Etanercept 58 Erythropoietic therapies may 58 Negative Syndrome 58 doxorubicin cyclophosphamide 58 comparator arm 58 Juvenile Idiopathic Arthritis 58 noncardiovascular mortality 58 dipyridamole plus 58 dose atorvastatin 58 AGILECT R 58 peg interferon 58 serum cortisol 58 rFVIIa 58 Nebulized 58 See CLINICAL PHARMACOLOGY 58 thromboembolic 58 Aptivus ® 58 RLS symptoms 58 lenalidomide Revlimid R 58 nab paclitaxel 58 FOLFIRI alone 58 dasatinib Sprycel 58 NIH CPSI 58 PANSS scores 58 baminercept 58 latanoprost 58 IU mL 58 antiretroviral naïve 58 OADs 58 ARIXTRA 58 variceal bleeding 58 adult chronic ITP 58 REYATAZ r 58 tolvaptan 58 virologic suppression 58 clopidogrel Plavix 58 overt nephropathy 58 urinary calcium excretion 58 Cutaneous T 58 Zometa hazard 58 mean serum phosphorus 58 IFN alfa 58 serum triglycerides 58 COPAXONE ® 58 RoACTEMRA 58 Median PFS 58 serum PSA 58 TAXUS Liberte Long 58 partial remissions 58 P = .# 58 conjunctival hyperemia 58 FOLFOX regimen 58 incidence ≥ 58 postmenopausal osteoporotic women 58 X ULN 58 Naive Patients 58 cardiac toxicity 58 MMSE score 58 pyridostigmine 58 Ejection Fraction 58 elevated serum creatinine 58 infliximab 58 CD4 + cell 58 Mean Symptom Complex 58 albumin excretion 58 undetectable HBV DNA 58 oocytes retrieved 58 K ras mutations 58 Unified Parkinson Disease 58 cardiovascular hospitalization 58 #mg QD [001] 58 Fulvestrant 58 elevated IOP 58 5-fluorouracil/leucovorin 58 efavirenz EFV 58 Y BOCS 58 everolimus eluting stents 58 Subgroup analyzes 58 dose cohort 58 achieve sustained virologic 58 pegylated interferon alpha 2a 58 tacrolimus ointment 58 nodular partial response 58 + PH# 58 dose colchicine 58 ALT normalization 58 ribavirin RBV 58 Skin sterol 58 fluvastatin 58 creatinine clearance CrCl 58 doxazosin 58 MULTAQ 58 certolizumab pegol 58 Partial Response 58 ADAS Cog 58 epoetin beta 58 μg kg 58 Major Adverse Cardiac 58 seroconverted 58 Drug eluting stent 58 paclitaxel cisplatin 58 TAXUS Stent 58 plasma creatinine 58 unstable angina pectoris 58 ALT elevations 58 cytopenias 58 Mg Usa 58 cells uL 58 FOLFOX 58 asymptomatic PAD 58 REMINYL ® 58 sd = 58 visceral metastases 58 melphalan prednisone 58 transaminase levels 58 divalproex 58 peginterferon alfa 58 confirmed thrombotic cardiovascular 58 reduce serum phosphate 58 abatacept 58 composite endpoint 58 ADAS cog 58 Arch Intern Med 58 IIIa inhibitors 58 #mg doses [002] 58 bivalirudin monotherapy 58 asthma exacerbation 58 corrected QT interval 58 conjugated equine estrogen 58 non valvular atrial 58 Clinically significant 58 hemoglobin concentrations 58 Pharmacokinetic 58 Tumor shrinkage 58 EBMT criteria 58 variceal hemorrhage 58 % CI #.#-#.# [001] 58 endometrial thickness 58 lispro alone 58 diuretic chlorthalidone 58 lactate dehydrogenase LDH 58 advanced adenomas 58 EGFR expressing mCRC 58 primary patency 58 somatostatin analog 58 fasting insulin 58 Betaferon R 58 relapsing multiple sclerosis 58 Hepatitis C Antiviral 58 Score IPSS 58 serum potassium levels 58 Elitek 58 CC genotype 58 umol L 58 quetiapine risperidone 58 nephrotoxicity 58 HIV HCV coinfected 58 bezafibrate 58 PROMACTA 58 Tipranavir 58 IBDQ 58 neutropenic fever 58 budesonide pMDI 58 activated partial thromboplastin 58 reintervention 58 Follicular Lymphoma 58 Decitabine 58 rebleeding 58 argatroban 58 #μg [002] 58 pulmonary capillary wedge 58 baseline serum creatinine 58 dosage regimens 58 platelet inhibition 58 NLX P# 58 Hodgkin lymphoma HL 58 multivariate adjustment 58 univariate 58 non splenectomized 58 Febrile neutropenia 58 macrovascular 58 viral suppression 58 EDARBI 58 postoperative complication 58 thyrotropin levels 58 P ≤ 58 Engerix B 58 perioperatively 58 autoantibody levels 58 INVEGA ® 58 mmHg systolic 58 apolipoprotein B 58 QTc interval 58 Mg Uk 58 mg/m2 dose 57 CLINICAL STUDIES 57 cyclophosphamide methotrexate 57 nmol liter 57 systolic hypertension 57 paroxetine Paxil 57 metastatic CRC 57 SUVmax 57 nocturnal hypoglycemia 57 gemcitabine cisplatin 57 myocardial reperfusion 57 mCi kg 57 fasting triglyceride levels 57 Pemetrexed 57 serum sodium 57 plasma renin activity 57 febrile neutropenia 57 aripiprazole 57 Virologic 57 ADCS ADL 57 seropositivity 57 microalbuminuria 57 Tiotropium 57 gadolinium enhancing lesions 57 beta blocker therapy 57 Peg IFN 57 bendamustine 57 histologically confirmed 57 Retreatment 57 pramipexole 57 nonfatal stroke 57 CHD mortality 57 entecavir 57 psoriatic arthritis PsA 57 androgen deprivation 57 tumor progression TTP 57 tamsulosin 57 moderately emetogenic 57 bone marrow reticulin deposition 57 cinacalcet 57 Teriflunomide 57 Fludarabine 57 PCWP 57 COZAAR 57 squamous histology 57 Visual Analog Scale 57 BEACOPP 57 Major Depressive Disorder 57 TNF blocker therapy 57 mTSS 57 glimepiride 57 ® emtricitabine 57 Secondary efficacy endpoints 57 serum triglyceride levels 57 achieved PASI 57 lactate dehydrogenase 57 secondary endpoint 57 paliperidone ER 57 irinotecan cisplatin 57 anastrozole 57 plasma leptin 57 transaminase elevations 57 Chronic Hepatitis C 57 cardiovascular calcification 57 ® lenalidomide 57 fraction LVEF 57 Raptiva r 57 virologic failures 57 diastolic BP 57 RAPAFLO R 57 MAGE A3 ASCI 57 infarct size 57 Betaferon ® 57 Negative Symptoms 57 distant metastasis 57 retinal vein occlusion 57 receiving SIMPONI 57 phonophobia 57 demonstrated clinically meaningful 57 postoperative delirium 57 hypomagnesemia 57 interferon alfa 2a 57 baseline CD4